Hims & Hers Health (NYSE:HIMS) Raised to “Hold” at Wall Street Zen

Hims & Hers Health (NYSE:HIMS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently weighed in on HIMS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Citigroup reduced their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Bank of America lifted their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Finally, Barclays upped their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Trading Up 0.0%

NYSE:HIMS opened at $28.15 on Friday. Hims & Hers Health has a one year low of $13.74 and a one year high of $65.30. The business has a fifty day moving average price of $32.11 and a 200-day moving average price of $26.06. The firm has a market capitalization of $6.57 billion, a price-to-earnings ratio of -44.68 and a beta of 2.40. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the firm posted $0.17 earnings per share. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. Sell-side analysts forecast that Hims & Hers Health will post -0.05 EPS for the current year.

Insider Activity

In related news, insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $141,435.00. Following the sale, the insider owned 6,790 shares of the company’s stock, valued at approximately $213,885. This trade represents a 39.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This trade represents a 11.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,176 shares of company stock valued at $2,523,401 in the last three months. 11.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the stock. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $11,520,000. Bank of New York Mellon Corp purchased a new position in shares of Hims & Hers Health in the second quarter worth $46,220,000. Handelsbanken Fonder AB boosted its position in shares of Hims & Hers Health by 4.0% during the second quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after acquiring an additional 2,300 shares during the last quarter. Valeo Financial Advisors LLC bought a new position in shares of Hims & Hers Health during the second quarter worth $225,000. Finally, FNY Investment Advisers LLC purchased a new position in Hims & Hers Health during the second quarter valued at $347,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management raised its full-year revenue outlook to approximately $3.1 billion–$3.3 billion, while second-quarter revenue increased 38% year over year to $753.2 million. The guidance suggests continued demand for Hims & Hers’ telehealth and weight-management offerings. Hims & Hers Raised Guidance
• Positive Sentiment: Bank of America and Needham analysts reportedly maintained constructive views on HIMS, supporting the bullish case that subscriber growth, expanding services, and the company’s longer-term healthcare platform can outweigh near-term volatility. Bank of America Analyst Forecast Needham Analyst Forecast
• Neutral Sentiment: Analyst opinion is divided: Citigroup issued a more pessimistic forecast, highlighting valuation and execution risks as Hims & Hers transitions its weight-loss business. Citigroup Forecast
• Negative Sentiment: The company’s gross margin fell six percentage points sequentially to 64% as branded GLP-1 drugs increased revenue but produced less favorable economics. The earnings report also included an adjusted loss of $0.37 per share, substantially below the $0.05 loss analysts expected, increasing concerns that growth is coming at the expense of profitability. Hims & Hers Margin Analysis
• Negative Sentiment: Several law firms, including Kaplan Fox, Kessler Topaz, Glancy Prongay Wolke, and Howard G. Smith, announced investigations into potential securities-law violations. These announcements are investor-solicitation notices rather than findings of wrongdoing, but they add headline, litigation, and reputational risk following the Federal Trade Commission’s lawsuit against the company. Kaplan Fox Investigation Kessler Topaz Investigation

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.